简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Research
HOME
·
China Southern Chinext Artificial Intelligence ETF
China Southern Chinext Artificial Intelligence ETF(159382) rises 3.65%, with the latest scale reaching 2.386 billion yuan
Tags:
ETF
159382.SZ
China Southern Chinext Artificial Intelligence ETF
2026-06-02
China Southern Chinext Artificial Intelligence ETF(159382) Rises 3.51%, Sees Share Growth of 86 Million Units Over the Past Two Weeks
Tags:
ETF
159382.SZ
China Southern Chinext Artificial Intelligence ETF
2026-05-07
China Southern Chinext Artificial Intelligence ETF(159382) Rises 3.31%, with AUM Growth of RMB 28.8601 Million Over Past Week
Tags:
ETF
159382.SZ
China Southern Chinext Artificial Intelligence ETF
2026-04-17
China Southern Chinext Artificial Intelligence ETF(159382) Rises 4.46%, Scale Grows by 1.683 Billion Yuan Over Past Six Months
Tags:
ETF
159382.SZ
China Southern Chinext Artificial Intelligence ETF
2026-04-16
Featured News
Finance
Marketingforce Management(02556.HK): Profit Forecast, Interim Revenue from AI Application Business Expected to Surge 112% to 134%
Finance
Hengrui Pharmaceuticals(01276.HK): Concentrated Solution for Injection HRS-8829 Receives Clinical Trial Approval Notice
Finance
MicroPort Scientific (00853.HK): Proposed Disposal of Controlling Stake in MicroPort Orthopedics (Shanghai) to Tinavi Medical
Finance
Renrui Human Resources(06919.HK): Non-executive Director Wang Xinjie Resigns; Gao Yunjie Appointed
Finance
Ubox Online (02429.HK): Full Circulation of H Shares Approved by HKEX
Finance
Chengdu Expressway (01785.HK): Signs Precast Concrete Component Procurement Contract for Chengdu-Wenjiang-Qionglai Expressway Expansion Project Worth Approximately RMB 234 Million
Finance
Prinx Chengshan (01809.HK): CEO Reshuffle – Che Baozhen Steps Down, Jiang Xizhou Appointed as President
Finance
Fameglow Holdings(03774.HK): Enters Technology Development Agreement with Sunseeker to Jointly Develop AI Anti-Aging Platform
Finance
Zhongtai Futures (01461.HK): Positive Profit Alert, Interim Net Profit Attributable to Parent Expected to Rise 190% to 210%
Finance
InnoCare Pharma Limited(09969.HK): Phase III Registrational Trial of Soficitinib (ICP-332) for Moderate-to-Severe Atopic Dermatitis Meets Primary Endpoint Successfully
Scan QR Code
Download App